會議背景：
醫藥及生物科技領域近年來蓬勃發展，國際化程度日漸提高。該領域的私募融資交易數量不斷攀升，2020 年度，其總融資金額超過 107 億美元，單筆融資規模約 4400 萬美元，同比增長 42%。我國 2020 年生物醫藥領域 IPO 融資總金額超 147 億美元，其中以腫瘤等領域創新藥公司投融資數額較大。由此所涉及的國際化戰略、投融資與并購布局策略、盡職調查、知識產權保護等問題逐漸成為焦點走入各界視野。
 
Background：
The fields of medicine and biotechnology have developed vigorously in
 recent  years, and the degree of internationalization is increasing day
by day. The number of private financing transactions in this field continues to rise. In 2020, the total financing amount exceeded US $10.7 billion, and the single financing scale was about US $44 million, a year-on-year increase of 42%.
China's total IPO Financing in the field of biopharmacy in 2020. The amount exceeds US $14.7 billion, of which the investment and financing amount of innovative drug companies in tumor and other fields is large. Therefore, the internationalization strategy, investment and financing,
M & A layout strategy, due diligence, intellectual property protection and other issues involved have gradually become the focus and come into the vision of all walks of life.
 
會議日期：2021年12月8號
會議地點：上海浦東嘉里大酒店F1，浦東新區花木路1388號
會議規模：60-70人
 
13:00-13:10 推介會歡迎辭  Opening Remarks
Intralinks
13:10-13:40 主題報告--浪潮之下：中國生物醫藥的創新現狀與未來風向
Session 1--Under the tide: innovation status and future direction of
biomedicine in China
徐佳熹 興業證券董事總經理，研究院副院長，醫藥行業首席分析師
Dr.Jiaxi XU,Managing Director,Industrial Securities Co.,Ltd.
13:40-14:10 中國生物醫藥產業合作與投融資報告發布
Session 2 -- China's biomedical industry cooperation and investment
and financing report
中國醫藥工業信息中心
14:10-14:40 主題報告—“生物醫藥在中國”
-推動醫藥研發創新和準入方面的全球化發展
-中國如何成功地將本土制藥能力從制造技術拓展到研發創新，并擁有更多的海外授權項目
Session 3 -- Pharma in China
- Driving global progress in innovation and access
-How successfully is China expanding its pharma capabilities beyond
manufacturing into innovation and having more license-out projects？
臧敬五博士，創始人、董事長，天境生物
Dr.Jingwu ZANG,Founder and Chairman,I-Mab Biopharma
14:40-15:00 茶歇  Coffee Break
15:00-15:30 主題報告--審而慎之：盡職調查在企業 IPO 以及并購等方向實踐問題
Session 4-- Practice of due diligence in corporate IPO and M & A
葉玉盛，合伙人，競天公誠律師事務所
Yusheng YE,Partner,Jingtian & Gongcheng LLP
15:30-16:00 主題報告—“合作研發”--一種強有力的關系組合，對未來的醫藥研發至關重要
Session 5 -- How Collaboration-A Powerful Relationship Combination Are Essential to the Future of Pharmacy R&D
張連山 博士，全球研發總裁，江蘇恒瑞醫藥股份有限公司
Dr.Lianshan ZHANG,President of Global R&D，Hengrui Pharmaceuticals
16:00-16:30 主題報告：從投資和融資的角度來看，生物制藥市場是否仍將“炙手可熱”？
Session 6 -- Will the biopharma market remain “hot” from an investment and funding perspective?
尹正，三一創新，創始合伙人
Dr. Jack YIN,Partner,TIF
16:30-17:00 License out的趨勢和策略
Trend and strategy of License out
富天，昂闊醫藥首席商務官、聯合創始人，昂闊醫藥
Andy Fu, PharmD, MBA,Co-Founder, Chief Business Officer,OnCusp Therapeutics 
17:00-17:45 圓桌討論—策略談：2021 中國生物醫藥與健康創新投融資焦點
Panel：2021 Investment and financing of biomedicine and health innovation in China Purchase focus
- 2021 上半年中國生物醫藥及健康領域并購活動及各市場 IPO 情況說明
2021 Description of M & A activities in the field of biomedicine and health in China and IPO in various markets in the first half of the year
- 疫情常態化與監管政策中的投融資變化與未來分析
Investment and financing changes and future analysis in epidemic
normalization and regulatory policies  
- 中國正在如何逐步融入國際醫藥市場
How is China evolving in the international pharma market to access landscape
毛化，合伙人&董事總經理，弗若斯特沙利文咨詢有限公司
袁寧，副首席商務官，復星醫藥
富天，昂闊醫藥首席商務官、聯合創始人，昂闊醫藥
巫薈，董事總經理，泉創資本
李嘉，首席財務官，榮昌生物
Fred MAO,Partner&Managing Director,Frost & Sullivan
Ning YUAN,Deputy Chief Business Officer,Fosun Pharma
Andy Fu, PharmD, MBA,Co-Founder, Chief Business Officer,OnCusp Therapeutics 
Dr.Marietta WU,Managing Director,Quan Capital
Jason Li,CFO,RemeGen Ltd.
 
活動免費，名額有限。掃碼報名，先到先得！
 
聯系人CONTACT：李女士 Miss Li
電話TEL：18317040595
郵件EMAIL：1583832312@qq.com